In this article, we will discuss the 8 Best CBD Stocks to Buy Right Now.
The CBD sector is showing signs of entering a more mature and sustainable growth phase. This shift is drawing renewed investor attention to CBD stocks. Industry analysts say the market is transitioning from the speculative boom that followed the 2018 US farm bill into a more disciplined sector driven by consumer demand, product innovation, operational discipline, and improving regulations.
In 2026, the cannabis industry is being defined by consolidation and a shift to sustainable profitability.
The long-term market opportunity remains significant. Grand View Research estimates that the global CBD market could expand from roughly $18.2 billion in 2025 to around $39.7 billion in 2033, reflecting a nearly 10% CAGR. This growth is expected to be driven by rising demand for CBD wellness products, including those targeting sleep, anxiety, and pain problems.
The rapid expansion of newer categories, such as CBD-based beverages, chocolates, gummies, and skincare products, is also fueling industry growth.
The broader cannabis sector sentiment has started to improve following challenges in recent years. Recent industry forecasts from Whitney Economics project a stronger US cannabis market in 2026 as companies consolidate operations and cut costs to focus on improving profitability and cash flow. For investors, many CBD stocks now offer exposure to a rapidly expanding market with substantial long-term growth potential.
That said, this article explores some of the best CBD stocks to buy right now.
Our Methodology
To compile the list of the 8 best CBD stocks to buy right now, we sifted through industry publications and reviewed financial media reports to identify companies that produce and sell cannabidiol (CBD) products. We ended up with more than a dozen stocks in our initial list and applied additional filters to pick out the best. We selected CBD stocks that hedge funds like and have at least 5% upside potential. The hedge fund data was sourced from Insider Monkey’s database as of Q1 2026. Finally, we ranked the stocks based on their price upside potential.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
Best CBD Stocks to Buy Right Now
8. Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Stock Upside Potential: 5.86%
Number of Hedge Fund Holders: 48
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) is one of the best CBD stocks to buy right now. The stock has gained almost 40% year-to-date, and analysts see more upside in it.
According to Jazz Pharmaceuticals’ Q1 2026 results released on May 5, revenue from CBD-based epilepsy drug Epidiolex rose 15% YoY to $250 million in that quarter. The increase was driven by continued strong demand for Epidiolex, which is used to treat severe forms of epilepsy. Outside the US, Epidiolex is marketed under the Epidyolex brand name.
Jazz has partnered with Nippon Zoki to commercialize Epidyolex in Japan as it works to expand the drug’s market. Epidiolex was Jazz’s second-largest business by revenue contribution in Q1 after the company’s sleep franchise.
Jazz’s consolidated revenue from the various business lines came to $1.1 billion, reflecting an increase of 19% YoY. The company delivered a net income of $293.1 million, compared with a net loss of $92.5 million a year ago.
Looking ahead, Jazz Pharmaceuticals anticipates full-year 2026 revenue of between $4.25 billion and $4.5 billion. The company is advancing its pipeline projects as it seeks to fuel long-term growth.
Jazz Pharmaceuticals PLC is a biopharmaceutical company whose programs include cannabinoid therapeutics. Its CBD-based blockbuster drug Epidiolex is used to treat severe epilepsy. The company was founded in 2003 and is based in Ireland.
7. Canopy Growth Corp (NASDAQ:CGC)
Stock Upside Potential: 18.88%
Number of Hedge Fund Holders: 11
Canopy Growth Corp (NASDAQ:CGC) is one of the best CBD stocks to buy right now. On May 7, Canopy Growth Corp announced the expansion of its cannabinoid softgel lineup. This two-fold expansion includes the launch of new pack sizes and the introduction of additional dosing options.
Regarding pack sizes, Canopy Growth has introduced new 30-pack and 90-pack formats of the softgel product. The company said that offering these formats reflect its commitment to improve patient access with targeted, need-stated products.
According to Canopy Growth, its existing 30-pack offering has performed strongly, so it’s building on that strength with the new pack offering. Andrew Bevan, Canopy Growth’s senior vice-president of medical, stated that they are focused on building a portfolio that reflects the feedback from patients and clinics.
So far, the success of the existing 30-pack formats has made the management understand that patients are looking for more value and greater access to cannabinoid formulations. With the expanded lineup, Canopy Growth says it delivers greater flexibility for patient dosing and improves affordability. The company distributes the cannabinoid softgel products through its medical division, Spectrum Therapeutics.
Canopy Growth Corp is a Canadian cannabis company based in Ontario. The company produces and distributes a wide variety of cannabis and hemp products for medical and recreational use. Its portfolio includes various types of hemp-derived CBD products, including gummies, oil drops, and softgels.
6. Cronos Group Inc (NASDAQ:CRON)
Stock Upside Potential: 39.35%
Number of Hedge Fund Holders: 16
Cronos Group Inc (NASDAQ:CRON) is one of the best CBD stocks to buy right now. The stock is up roughly 40% over the past year, and analysts see it rising further over the next 12 months.
On May 11, Cronos Group Inc reported Q1 2026 results that surpassed expectations. Net revenue jumped 40% YoY to a record $45.2 million and exceeded analysts’ forecast of $42.23 million. The company said the topline growth was driven by strong cannabis flower sales in Canada, Israel, and other countries.
Cronos posted a net income of $15.7 million, compared to $7.7 million in the prior year. The company said this increase was primarily supported by higher gross profit and other income. The EPS came in at $0.04, above the $0.02 that analysts expected.
Lord Jones, the company’s brand of CBD products that serves the premium consumer market, continued to expand its market share in Q1. In Canada’s chocolate cannabis edibles category, the brand held a 9.1% market share and ranked third in the country. Lord Jones also expanded into Israel’s medical cannabis market in Q1 and was met with strong demand for its premium flower strains.
Looking ahead, Cronos counts on its acquisition of CanAdelaar to accelerate its growth in Europe. It expects to close the acquisition in the summer of 2026.
Cronos Group Inc is a Canadian company that produces and sells a broad variety of cannabis and hemp-derived products. Its product portfolio includes dried flowers, pre-rolls, vapes, oils, and edibles, and these are sold under various brand names, such as Lord Jones.
5. Tilray Brands Inc (NASDAQ:TLRY)
Stock Upside Potential: 50.74%
Number of Hedge Fund Holders: 10
Tilray Brands Inc (NASDAQ:TLRY) is one of the best CBD stocks to buy right now. Although Tilray Brands Inc stock is up only a modest 19% over the past year, analysts see the stock soaring more than 50% over the next 12 months.
On May 26, Tilray Medical joined talks on medical cannabis regulations in London. Tilray Medical is a subsidiary of Tilray Brands that offers a wide range of medical-grade CBD-products. The London talks brought together healthcare professionals, researchers, industry leaders, and policymakers to explore the future of medical cannabis innovation and regulation in Europe.
The forum included a panel discussion focused on clinical research, patient outcomes, and public health data to help shape evidence-based regulatory approaches.
According to José Tempero, Tilray Medical’s director of international medical affairs, the European medical cannabis field continues to evolve. In light of this, research and clinical evidence are critical to developing responsible frameworks and improving patient access.
Tilray Medical is a leading supplier of medical cannabis across five continents. According to Tilray Brands, the medical subsidiary has deep regulatory expertise and is well-positioned to continue advancing patient care across international markets.
Tilray Brands Inc is a consumer packaged goods company. Its portfolio includes craft beer, spirits, medical and adult-use cannabis, and hemp wellness products. It operates dozens of brands and has footprints in more than 20 countries across the Americas and Europe.
4. Village Farms International Inc (NASDAQ:VFF)
Stock Upside Potential: 77.88%
Number of Hedge Fund Holders: 13
Village Farms International Inc (NASDAQ:VFF) is one of the best CBD stocks to buy right now. Village Farms stock has gained more than 110% over the past year, and analysts expect it to rise more than 77% over the next 12 months.
Village Farms International Inc reported its Q1 2026 results on May 11, revealing a 27% YoY jump in net sales to $50.2 million. This topline growth was driven by international export sales that soared 171% YoY to a record $14.6 million. The Netherlands was one of the company’s fastest-growing international markets, with sales there surging 448%. In Germany, the company continued to grow its market share and benefit from stable pricing.
Village Farms delivered net income of $4.8 million, reflecting a 68% YoY increase. It exited the quarter with $50.5 million in cash.
Village Farms’ Pure Sunfarms brand, through which it sells various CBD products, continued to expand its share of the dried flower format in Canada. Village Farms has recently expanded its cannabis production capacity and expects the expansion projects to fuel sales growth in the remainder of 2026 and into 2027.
Village Farms International Inc is a global cannabis company based in Canada. It produces and distributes a wide variety of cannabis and hemp-derived products for wellness and recreational use. Village Farms also has agricultural and clean energy interests.
3. Organigram Global Inc (NASDAQ:OGI)
Stock Upside Potential: 142.91%
Number of Hedge Fund Holders: 4
Organigram Global Inc (NASDAQ:OGI) is one of the best CBD stocks to buy right now. Analysts expect Organigram Global shares to explode by more than 140% over the next 12 months.
On May 12, Organigram Global Inc reported its March quarter results and issued guidance for 2026 revenue. The March quarter report showed net revenue declined 9% YoY to $59.8 million. Adjusted EBITDA of $0.9 million compared with $4.9 million a year ago.
The company said that weakness in its vapes business, infused pre-roll production challenges, and slower industry growth led to the quarterly declines. The company booked lower vape and pre-roll sales in the latest quarter than it did a year ago.
Organigram CEO James Yamanaka said they acted quickly to address these issues. As a result, product enhancements and operational adjustments that the company implemented are stabilizing performance. The company also expects the improvement in yields and flower potency as well as the contribution from Sanity Group to drive performance improvement in the second half of 2026.
Sanity is a Germany-based cannabis company that Organigram acquired at the end of the March quarter. Sanity has a diversified cannabis business and expanding operations across Europe, including footprints in the UK, Poland, Switzerland, and Czechia. Organigram expects Sanity to generate roughly €25 million in quarterly revenue over the next year. In light of the expected Sanity contribution, Organigram raised its 2026 revenue outlook to $350 million from the previous $300 million.
Organigram Global Inc is a Canadian company that grows cannabis and manufactures a variety of cannabis-derived products for recreational and wellness use. Its product range includes CBD-infused edibles under the Monjour brand.
2. cbdMD Inc (NYSEAMERICAN:YCBD)
Stock Upside Potential: 162.85%
Number of Hedge Fund Holders: N/A
cbdMD Inc (NYSEAMERICAN:YCBD) is one of the best CBD stocks to buy right now. The stock has gained around 35% over the past six months, and analysts see more upside potential, expecting the stock to surge more than 160% over the next 12 months.
cbdMD Inc reported its March quarter results on May 14. The report showed revenue increased 19% YoY and 12% sequentially to $5.6 million. The company said the topline growth reflected continued momentum in its core business as well as contributions from the newly acquired Bluebird Botanicals.
Bluebird is a long-standing and respected brand in the CBD industry. According to Ronan Kennedy, the CEO of CbdMD, the Bluebird acquisition is a case study for what they can do and sets the template for additional strategic acquisitions.
Looking ahead, the CbdMD management expects Bluebird to contribute more to both its topline and earnings as operational efficiencies are realized and additional products are rolled out. With the integration of Bluebird, CbdMD expects to realize operational efficiencies through consolidated manufacturing, supply chain, and shared services. In addition, the management expects the expanded product offering and cross-brand distribution to accelerate revenue growth.
Beyond the expected Bluebird contribution, the CbdMD management is also excited about the opportunities in the CMS BEI Medicare pathway activation. This program allows participants in certain centers to consult about incorporating hemp products to improve symptom control.
cbdMD Inc produces and distributes hemp-derived CBD products for wellness. Its portfolio includes CBD oils, gummies, and sleep aids. While the company primarily offers CBD products for human consumption, it also provides pet-specific products.
1. SNDL Inc (NASDAQ:SNDL)
Stock Upside Potential: 193.10%
Number of Hedge Fund Holders: 13
SNDL Inc (NASDAQ:SNDL) is one of the best CBD stocks to buy right now. SNDL Inc reported its Q1 2026 results on April 29, revealing a 4.4% YoY drop in revenue to $195.9 million. The company said it faced market headwinds in both its liquor and cannabis segments during the quarter.
SNDL’s combined cannabis segment revenue declined 3.8% to $91.8 million, and operating loss widened 20% to $5.8 million. The cannabis segment houses the company’s portfolio of CBD-infused products, such as the Pearls by Gron gummies.
Looking ahead, SNDL CEO Zach George said they anticipate improvements in the cannabis market in the back half of 2026. Citing the company’s solid financial position, the CEO stated that SNDL is well-positioned to take advantage of both organic and inorganic opportunities to enhance its portfolio and accelerate growth. SNDL closed Q1 with $213.4 million in cash and no debt.
The management mentioned disciplined capital allocation as a major priority. The team is also pursuing efficiency initiatives and profit-enhancement measures as it adjusts to the reality of the current market conditions. As part of the profit-enhancement efforts, SNDL is launching initiatives expected to add $20 million in operating income over the remainder of 2026.
Canada-based SNDL Inc is engaged in the liquor and cannabis retail businesses. The company’s cannabis division produces and distributes a suite of products, including CBD-based topicals, beverages, and edibles like gummies and chocolates.
READ NEXT: 10 Most Buzzing AI Semiconductor Stocks to Buy in 2026 and 11 Best Medical Technology Stocks to Buy Right Now.
